BE1025210B1 - Conjugues immunogenes et leur utilisation - Google Patents

Conjugues immunogenes et leur utilisation Download PDF

Info

Publication number
BE1025210B1
BE1025210B1 BE2017/5855A BE201705855A BE1025210B1 BE 1025210 B1 BE1025210 B1 BE 1025210B1 BE 2017/5855 A BE2017/5855 A BE 2017/5855A BE 201705855 A BE201705855 A BE 201705855A BE 1025210 B1 BE1025210 B1 BE 1025210B1
Authority
BE
Belgium
Prior art keywords
nomv
antigen
saccharide
immunogenic
nomvs
Prior art date
Application number
BE2017/5855A
Other languages
English (en)
French (fr)
Other versions
BE1025210A1 (fr
Inventor
Renzo Alfini
Francesca Micoli
Allan James Saul
Original Assignee
Glaxosmithkline Biologicals Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1619946.5A external-priority patent/GB201619946D0/en
Priority claimed from GBGB1712096.5A external-priority patent/GB201712096D0/en
Application filed by Glaxosmithkline Biologicals Sa filed Critical Glaxosmithkline Biologicals Sa
Publication of BE1025210A1 publication Critical patent/BE1025210A1/fr
Application granted granted Critical
Publication of BE1025210B1 publication Critical patent/BE1025210B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A61K39/015—Hemosporidia antigens, e.g. Plasmodium antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0258—Escherichia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0275—Salmonella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0283—Shigella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/116—Polyvalent bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55588—Adjuvants of undefined constitution
    • A61K2039/55594—Adjuvants of undefined constitution from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/64—Medicinal preparations containing antigens or antibodies characterised by the architecture of the carrier-antigen complex, e.g. repetition of carrier-antigen units
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Dispersion Chemistry (AREA)
  • Biochemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
BE2017/5855A 2016-11-25 2017-11-23 Conjugues immunogenes et leur utilisation BE1025210B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1619946.5 2016-11-25
GBGB1619946.5A GB201619946D0 (en) 2016-11-25 2016-11-25 Conjugated immunogenic derivatives and use thereof
GBGB1712096.5A GB201712096D0 (en) 2017-07-27 2017-07-27 Immunogenic conjugates and use thereof

Publications (2)

Publication Number Publication Date
BE1025210A1 BE1025210A1 (fr) 2018-12-05
BE1025210B1 true BE1025210B1 (fr) 2018-12-12

Family

ID=60702606

Family Applications (1)

Application Number Title Priority Date Filing Date
BE2017/5855A BE1025210B1 (fr) 2016-11-25 2017-11-23 Conjugues immunogenes et leur utilisation

Country Status (9)

Country Link
US (1) US12036285B2 (cg-RX-API-DMAC7.html)
EP (1) EP3544625A2 (cg-RX-API-DMAC7.html)
JP (2) JP7100031B2 (cg-RX-API-DMAC7.html)
CN (1) CN110214022A (cg-RX-API-DMAC7.html)
BE (1) BE1025210B1 (cg-RX-API-DMAC7.html)
BR (1) BR112019010227A2 (cg-RX-API-DMAC7.html)
CA (1) CA3044569A1 (cg-RX-API-DMAC7.html)
MX (1) MX2019006104A (cg-RX-API-DMAC7.html)
WO (1) WO2018096007A2 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE052751T2 (hu) * 2016-11-25 2021-05-28 Glaxosmithkline Biologicals Sa Natív OMV-antigén konjugátumok és alkalmazásuk
US12036285B2 (en) 2016-11-25 2024-07-16 Glaxosmithkline Biologicals Sa Immunogenic conjugates and use thereof
GB201712824D0 (en) * 2017-08-10 2017-09-27 Glaxosmithkline Biologicals Sa Multi-functionalized nOMV Conjugates
CN111358942A (zh) * 2018-12-25 2020-07-03 国家纳米科学中心 一种疫苗及其制备方法
JP7462864B2 (ja) * 2019-04-19 2024-04-08 国立感染症研究所長 メンブレンヴェシクル
WO2021031270A1 (zh) * 2019-08-22 2021-02-25 四川大学 细菌膜囊泡及其分离制备系统和方法
US12649150B2 (en) 2024-05-29 2026-06-09 Cassiopea LLC Enzyme-decorated nanocatalysts

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013006055A1 (en) * 2011-07-07 2013-01-10 De Staat Der Nederlanden, Vert. Door De Minister Van Vws A process for detergent-free production of outer membrane vesicles
WO2016184860A1 (en) * 2015-05-18 2016-11-24 Universita' Degli Studi Di Trento Immunogenic compositions containing bacterial outer membrane vesicles and therapeutic uses thereof

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4271147A (en) 1980-01-10 1981-06-02 Behringwerke Aktiengesellschaft Process for the isolation of membrane proteins from Neisseria meningitidis and vaccines containing same
US4459286A (en) 1983-01-31 1984-07-10 Merck & Co., Inc. Coupled H. influenzae type B vaccine
NZ214503A (en) 1984-12-20 1990-02-26 Merck & Co Inc Covalently-modified neutral bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins, and methods of preparing such polysaccharides and conjugates
US4707543A (en) 1985-09-17 1987-11-17 The United States Of America As Represented By The Secretary Of The Army Process for the preparation of detoxified polysaccharide-outer membrane protein complexes, and their use as antibacterial vaccines
EP0467714A1 (en) 1990-07-19 1992-01-22 Merck & Co. Inc. The class II protein of the outer membrane of neisseria meningitidis
CA2264970A1 (en) 1998-03-10 1999-09-10 American Cyanamid Company Antigenic conjugates of conserved lipolysaccharides of gram negative bacteria
NZ571167A (en) 1999-04-30 2010-05-28 Novartis Vaccines & Diagnostic Fragments from Neisseria protein ORF 953 and their use in medicaments and diagnostic reagents
AU2818101A (en) 2000-01-25 2001-08-07 University Of Queensland, The proteins comprising conserved regions of neisseria meningitidis surface antigen NhhA
GB0103171D0 (en) 2001-02-08 2001-03-28 Smithkline Beecham Biolog Vaccine composition
WO2006124712A2 (en) 2005-05-16 2006-11-23 Merck & Co., Inc. A method for improving the immunogenicity of plasmodium antigens
WO2006123164A2 (en) 2005-05-19 2006-11-23 The Edward Jenner Institute For Vaccine Research Lps-binding and bactericidal cytokines and interferons
EP2852414B9 (en) 2012-05-22 2020-12-09 GlaxoSmithKline Biologicals SA Meningococcus serogroup x conjugate
EP2870974A1 (en) * 2013-11-08 2015-05-13 Novartis AG Salmonella conjugate vaccines
EP3223847A1 (en) * 2014-11-28 2017-10-04 Janssen Vaccines & Prevention B.V. Meningitis b vaccine
EP3482387B1 (en) 2016-07-11 2025-09-03 BOE Technology Group Co., Ltd. Chip on film, flexible display apparatus having the same, and fabricating method thereof
US12036285B2 (en) 2016-11-25 2024-07-16 Glaxosmithkline Biologicals Sa Immunogenic conjugates and use thereof
HUE052751T2 (hu) 2016-11-25 2021-05-28 Glaxosmithkline Biologicals Sa Natív OMV-antigén konjugátumok és alkalmazásuk

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013006055A1 (en) * 2011-07-07 2013-01-10 De Staat Der Nederlanden, Vert. Door De Minister Van Vws A process for detergent-free production of outer membrane vesicles
WO2016184860A1 (en) * 2015-05-18 2016-11-24 Universita' Degli Studi Di Trento Immunogenic compositions containing bacterial outer membrane vesicles and therapeutic uses thereof

Non-Patent Citations (11)

* Cited by examiner, † Cited by third party
Title
ALI FARJAH ET AL: "Immunological evaluation of an alginate-based conjugate as a vaccine candidate against Pseudomonas aeruginosa", ACTA PATHOLOGICA, MICROBIOLOGICA ET IMMUNOLOGICA SCANDINAVICA, vol. 123, 3 December 2014 (2014-12-03), pages 175 - 183, XP055478624 *
DEVI S J N ET AL: "Binding diversity of monoclonal antibodies to alpha(2-->8) polysialic acid conjugated to outer membrane vesicle via adipic acid dihydrazide", FEMS IMMUNOLOGY AND MEDICAL MICROBIOLOGY, ELSEVIER SCIENCE B.V., AMSTERDAM, NL, vol. 14, no. 4, 1 July 1996 (1996-07-01), pages 211 - 220, XP002315243, ISSN: 0928-8244 *
DEVI S J N ET AL: "PRECLINICAL EVALUATION OF GROUP B NEISSERIA MENINGITIDIS AND ESCHERICHIA COLI K92 CAPSULAR POLYSACCHARIDE-PROTEIN CONJUGATE VACCINES IN JUVENILE RHESUS MONKEYS", INFECTION AND IMMUNITY,, vol. 65, no. 3, 1 March 1997 (1997-03-01), pages 1045 - 1052, XP000872520, ISSN: 0019-9567 *
FUKASAWA LUCILA O ET AL: "OPTIMIZATION OF THE CONJUGATION METHOD FOR A SEROGROUP B/C MENINGOCOCCAL VACCINE", BIOTECHNOLOGY AND APPLIED BIOCHEMI, ACADEMIC PRESS, US, vol. 45, no. PT3, 1 October 2006 (2006-10-01), pages 141 - 146, XP009081494, ISSN: 0885-4513 *
LUCILA O FUKASAWA ET AL: "Adjuvant can improve protection induced by OMV vaccine against Neisseria meningitidis serogroups B/C in neonatal mice", FEMS IMMUNOLOGY AND MEDICAL MICROBIOLOGY., vol. 41, no. 3, 1 July 2004 (2004-07-01), NL, pages 205 - 210, XP055478327, ISSN: 0928-8244, DOI: 10.1016/j.femsim.2004.03.005 *
NANCY L. PRICE ET AL: "Glycoengineered Outer Membrane Vesicles: A Novel Platform for Bacterial Vaccines", SCIENTIFIC REPORTS, vol. 6, no. 1, 22 April 2016 (2016-04-22), XP055478616, DOI: 10.1038/srep24931 *
NATHAN J ALVES ET AL: "Emerging therapeutic delivery capabilities and challenges utilizing enzyme/protein packaged bacterial vesicles", THERAPEUTIC DELIVERY, vol. 6, no. 7, 1 July 2015 (2015-07-01), GB, pages 873 - 887, XP055386958, ISSN: 2041-5990, DOI: 10.4155/tde.15.40 *
S. D. SIADAT ET AL: "Evaluation of Serum Bactericidal Activity Specific for Neisseria meningitidis Serogroup A and B: Effect of Immunization with Neisseria meningitidis Serogroup A Polysaccharide and Serogroup B Outer Membrane Vesicle Conjugate as a Bivalent Meningococcus Vaccine Candidate", RESEARCH JOURNAL OF MICROBIOLOGY, vol. 2, no. 5, 1 January 2007 (2007-01-01), pages 436 - 444, XP055478324 *
SEYED DAVAR SIADAT ET AL: "Preparation and Evaluation of a New Lipopolysaccharide-based Conjugate as a Vaccine Candidate for Brucellosis", OSONG PUBLIC HEALTH AND RESEARCH PERSPECTIVES,, vol. 6, no. 1, 1 February 2015 (2015-02-01), pages 9 - 13, XP009503435, ISSN: 2210-9099, [retrieved on 20141218], DOI: 10.1016/J.PHRP.2014.10.012 *
W D ZOLLINGER ET AL: "Bactericidal antibody responses of juvenile rhesus monkeys immunized with group B Neisseria meningitidis capsular polysaccharide-protein conjugate vaccines", INFECTION AND IMMUNITY, 1 March 1997 (1997-03-01), UNITED STATES, pages 1053 - 1060, XP055478620, Retrieved from the Internet <URL:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC175087/pdf/651053.pdf> *
ZHANG LAN ET AL: "Improving the immunogenicity of a trivalentNeisseria meningitidisnative outer membrane vesicle vaccine by genetic modification", VACCINE, ELSEVIER, AMSTERDAM, NL, vol. 34, no. 35, 2 July 2016 (2016-07-02), pages 4250 - 4256, XP029644903, ISSN: 0264-410X, DOI: 10.1016/J.VACCINE.2016.05.049 *

Also Published As

Publication number Publication date
EP3544625A2 (en) 2019-10-02
JP7439174B2 (ja) 2024-02-27
JP2019535775A (ja) 2019-12-12
WO2018096007A3 (en) 2018-11-15
WO2018096007A2 (en) 2018-05-31
US12036285B2 (en) 2024-07-16
MX2019006104A (es) 2019-08-21
BR112019010227A2 (pt) 2019-10-08
BE1025210A1 (fr) 2018-12-05
JP2022130637A (ja) 2022-09-06
CN110214022A (zh) 2019-09-06
CA3044569A1 (en) 2018-05-31
JP7100031B2 (ja) 2022-07-12
US20230137821A1 (en) 2023-05-04

Similar Documents

Publication Publication Date Title
BE1025443B1 (fr) CONJUGUES nOMV-ANTIGENE ET LEUR UTILISATION
JP7439174B2 (ja) 免疫原性コンジュゲート及びその使用
TWI789357B (zh) 多價肺炎球菌多醣-蛋白質共軛物組成物(二)
TWI826420B (zh) 多價肺炎球菌多醣-蛋白質共軛物組成物
BE1024361B1 (fr) Composition immunogene
TWI770044B (zh) 多價肺炎球菌多醣-蛋白質共軛物組成物(一)
BE1022878B1 (fr) Vaccins anti-meningococciques
TWI919324B (zh) 包含結合之莢膜醣抗原的免疫原組合物及其用途
US20240293524A1 (en) MULTIPLE FUNCTIONALIZED noMV CONJUGATES
EP0914152A1 (fr) Complexe immunogene, son utilisation, son procede de preparation et vaccin le contenant
EP2429658B1 (fr) Procédé pour adjuver le lipopolysaccharide (LPS) des bactéries à gram-négatif

Legal Events

Date Code Title Description
FG Patent granted

Effective date: 20181212